A Study of FRaDCs for Ovarian Cancer
Conditions:  Fallopian Tube Carcinosarcoma;  Primary Peritoneal Carcinosarcoma;  Recurrent Fallopian Tube Carcinoma;  Recurrent Fallopian Tube Clear Cell Adenocarcinoma;  Recurrent Fallopian Tube Endometrioid Adenocarcinoma;  Recurrent Fallopian Tube High Grade Serous Adenocarcinoma;  Recu rrent Ovarian Carcinoma;  Recurrent Ovarian Carcinosarcoma;  Recurrent Ovarian Clear Cell Adenocarcinoma;  Recurrent Ovarian Endometrioid Adenocarcinoma;  Recurrent Ovarian High Grade Serous Adenocarcinoma;  Recurrent Primary Peritoneal Carcinoma;  Recurrent Primary Periton eal Clear Cell Adenocarcinoma;  Recurrent Primary Peritoneal Endometrioid Adenocarcinoma;  Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma Interventions:  Procedure: Biopsy;  Procedure: Biospecimen Collection;  Procedure: Computed Tomography;  Procedure: Magnetic Resonance Imaging;  Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine;  Biological: Pembrolizumab;  Procedure: Pheresis Sponsor:  Mayo Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Carcinosarcoma | Endometrial Cancer | Endometrioid Carcinoma | Fallopian Tube Cancer | Ovarian Cancer | Ovaries | Research | Serous Carcinoma | Study | Vaccines